The reiteration of a Buy rating and maintenance of a $19 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Travere Therapeutics. This endorsement reaffirms the firm's confidence in the company's future performance and potential to reach the specified price target, likely leading to increased investor interest and potentially a positive short-term impact on the stock price.